Selexipag denied as non-formulary by Humana?

Humana's specific coverage criteria for selexipag are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Selexipag as Non-Formulary

Selexipag is a specialty-tier drug for pulmonary arterial hypertension (PAH). Humana's formulary does not automatically include every FDA-approved specialty agent, and selexipag may be placed on a non-preferred or excluded tier for a given plan year. A non-formulary denial means the plan will not cover the drug at the standard cost-sharing level — but it does not mean the drug is unavailable or that you have exhausted your options.

## Why This Denial Is Appealable

Federal regulations require plans to have an exceptions process. If no formulary alternative is clinically appropriate for you — because you have already tried and failed alternatives, or because your prescriber documents a clinical reason why only selexipag will work — you can request a formulary exception. This is separate from, and often faster than, a full medical-necessity appeal.

## Your Federal Appeal Rights

• Formulary exception request: File this first. Your prescriber must submit a statement explaining why the formulary alternatives are contraindicated, have been tried and failed, or are otherwise not clinically appropriate for your specific situation.
• ACA §2719 / External Review: If the formulary exception is denied and your plan is subject to ACA requirements, you may escalate to independent external review within approximately four months of the denial.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review and must receive a written explanation citing the specific formulary criteria and clinical guidelines applied.
• Expedited pathway: Available if standard timelines would seriously jeopardize your health.

## Appeal Timeline

1. Request the formulary exception simultaneously with or immediately after the initial denial — do not wait for an internal appeal denial to begin this process. 2. If the exception is denied, file an internal appeal and request external review if the internal appeal fails. 3. Document every contact with Humana in writing.

## Documentation to Gather

• Formulary alternative trial history: For each drug Humana lists as a formulary alternative, provide dates trialed, doses used, and reasons for failure or contraindication — from actual chart notes, not just a prescriber attestation.
• Diagnosis confirmation: Records establishing PAH diagnosis (right-heart catheterization, functional class documentation).
• Prescriber exception letter: A letter specifically addressing each formulary alternative and explaining why selexipag is the medically necessary choice for this patient.
• Current clinical status: Recent labs, functional assessments, and any evidence of urgency.

## Criteria-Mapping Structure

Obtain Humana's formulary exception criteria and their current PAH drug list. For each formulary alternative identified, document the specific reason it is not appropriate. Cross-reference with the FDA-approved prescribing information for selexipag to confirm the indication aligns. Present a structured table matching each plan requirement to the corresponding chart evidence.